Experimental combo aims to tackle Hard-to-Treat prostate cancer
NCT ID NCT05743621
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called TVB-2640 combined with the standard drug enzalutamide (Xtandi) in 30 men whose prostate cancer has spread and stopped responding to hormone therapy. The main goal is to find the safest dose of TVB-2640 when used with enzalutamide and to track any side effects. Participants will be followed for about 12 to 24 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TVB-2640 (a fatty acid synthase inhibitor) combined with enzalutamide (Xtandi)
- What this could lead to
- If this combination proves safe, it could lead to a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 30 participants, focused on safety and dosing. It is too small and early to know if the combination actually works against cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Weill Cornell Medicine/NewYork-Presbyterian Hospital
RECRUITINGNew York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new daily pill slow advanced prostate cancer?
- Radiation plus hormone therapy may slow resistant prostate cancer
- Real-World data may reveal Pluvicto's true impact on advanced prostate cancer survival
- Mapping the next steps: how men with advanced prostate cancer are treated after standard therapies fail
- Massive data dive aims to uncover best prostate cancer treatments in real life
- New pill aims to shrink Hard-to-Treat cancers